Retro Biosciences
artifactAI & Compute · Biotech & Transhumanism
One of tech's biggest names is betting nearly a billion dollars that AI can add ten healthy years to your life.
Who they are
Retro Biosciences, a biotech startup backed by OpenAI's Sam Altman.
What they do
The engine treats it as an attempt to use AI to reverse cellular aging and extend the healthy human lifespan.
How it works
Altman put in $180 million in 2022, and OpenAI deployed a biology-focused AI called GPT-4b micro that treats protein sequences like a programming language; it redesigned the 'Yamanaka factors' used to rejuvenate cells and got a reported 50-fold jump in efficiency. The startup went from that $180M seed to a $1B Series A at a $5B valuation.
Why it matters
It matters because it puts control over directed biological aging in the hands of one AI-owning company, a private grip on the technology of staying young.
The engine's record — word for word
Biotechnology startup. Altman invested $180M (2022). Aims to extend healthy human lifespan by 10 years through cellular reprogramming, autophagy, plasma-inspired therapeutics. OpenAI deployed GPT-4b micro — biology-focused AI treating protein sequences as programmable language. Redesigned Yamanaka factors (RetroSOX, RetroKLF) achieving 50-fold increase in cellular reprogramming efficiency. AI-driven biological engineering achieving results traditional science cannot match at scale. Report #60: GPT-4b micro achieved 50x efficiency in Yamanaka factor redesign. $180M→$1B Series A at $5B valuation. Captive AI monopoly over directed biological evolution.
Follow the trail
Walk this on the live map →